Drug Trial Radar · NCT03758365
Evaluation of the Vasoconstriction Properties of MC2-01 Cream
Last checked: Nov 20, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Nov 5, 2018
Primary completion
Nov 23, 2018
Study completion Nov 23, 2018
Sponsor
- Lead sponsor
- MC2 TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this trial is to compare the vasoconstriction potential
Conditions
- Vasoconstriction
Interventions
MC2-01 CreamDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Clobetasol Propionate 0.05% LotionDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Betamethasone Dipropionate 0.05% CreamDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Triamcinolone Acetonide 0.1% CreamDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Hydrocortisone Butyrate 0.1% CreamDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Desonide 0.05% CreamDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
VehicleDrug
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and VehicleTime frame: Day 2
- Compare Local Tolerability of the MC2-01 Cream With Active Comparators and VehicleTime frame: Day 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CPCAD
Nice, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.